Arcturus Therapeutics (NASDAQ:ARCT) Given New $19.00 Price Target at Leerink Partners

Arcturus Therapeutics (NASDAQ:ARCT) had its price objective raised by analysts at Leerink Partners from $13.00 to $19.00 in a research note issued on Friday, Benzinga reports. The firm presently has an “outperform” rating on the biotechnology company’s stock. Leerink Partners’ price objective would indicate a potential upside of 47.63% from the company’s previous close.

Several other research analysts also recently commented on the stock. BTIG Research dropped their target price on shares of Arcturus Therapeutics from $23.00 to $20.00 and set a “buy” rating on the stock in a report on Thursday, September 24th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arcturus Therapeutics in a research report on Thursday, September 24th. Weiss Ratings reissued a “sell (d-)” rating on shares of Arcturus Therapeutics in a report on Friday, July 17th. Roth Capital reissued a “buy” rating and issued a $41.00 price target on shares of Arcturus Therapeutics in a report on Wednesday, September 2nd. Finally, Wall Street Zen cut shares of Arcturus Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, October 4th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Arcturus Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $22.00.

Arcturus Therapeutics Stock Performance

NASDAQ:ARCT opened at $12.87 on Friday. The company has a market capitalization of $365.77 million, a P/E ratio of -3.89 and a beta of 2.48. The stock’s 50 day moving average price is $12.59 and its 200 day moving average price is $9.26. Arcturus Therapeutics has a 52 week low of $5.50 and a 52 week high of $24.17.

Arcturus Therapeutics (NASDAQ:ARCT) last released its quarterly earnings data on Friday, August 7th. The biotechnology company reported ($0.84) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.00) by $0.16. Arcturus Therapeutics had a negative net margin of 317.62% and a negative return on equity of 46.54%. The business had revenue of $2.96 million during the quarter, compared to analyst estimates of $3.11 million. As a group, sell-side analysts forecast that Arcturus Therapeutics will post -3.48 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Versant Capital Management Inc boosted its position in Arcturus Therapeutics by 648.6% in the 3rd quarter. Versant Capital Management Inc now owns 3,032 shares of the biotechnology company’s stock valued at $42,000 after buying an additional 2,627 shares during the last quarter. Two Sigma Securities LLC bought a new stake in shares of Arcturus Therapeutics during the second quarter worth $80,000. Diversify Advisory Services LLC acquired a new position in shares of Arcturus Therapeutics during the second quarter valued at $91,000. ADAR1 Capital Management LLC bought a new position in Arcturus Therapeutics in the first quarter valued at about $116,000. Finally, Corient Private Wealth LP bought a new position in Arcturus Therapeutics in the second quarter valued at about $117,000. Institutional investors and hedge funds own 94.54% of the company’s stock.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc is a biotechnology company focused on developing medicines based on messenger RNA (mRNA) and other RNA technologies. Headquartered in San Diego, California, the company uses its proprietary LUNAR lipid-mediated delivery platform and STX self-amplifying mRNA technology to design and deliver RNA-based therapeutics and vaccines.

The company’s research and development activities address rare diseases, infectious diseases, respiratory conditions and other areas of significant unmet medical need.